Skip to main content
Equibles

Khoso Baluch

Board Member

Processa Pharmaceuticals, Inc. (PCSA)

Equibles does not estimate personal net worth.

About Khoso Baluch

Khoso Baluch is recorded as Board Member at Processa Pharmaceuticals, Inc. (PCSA) since January 1, 2022. The newest filing on record that lists Khoso Baluch as Board Member at Processa Pharmaceuticals, Inc. (PCSA) is dated June 18, 2026. Khoso Baluch was last confirmed as Board Member at CorMedix Inc. (CRMD) in a filing dated November 4, 2020. Earlier roles on record: CEO at CorMedix Inc. (CRMD) until October 4, 2021 and Board Member at Longeveron Inc. (LGVN) until November 7, 2025. Longeveron Inc. reported in an 8-K filed November 12, 2025 that Khoso Baluch resigned as Board of Directors, effective November 7, 2025. The proxy statement of CorMedix Inc. reports total compensation of $2,596,173 for Khoso Baluch in fiscal 2021, including a base salary of $366,700. Disclosed compensation is on record for 3 fiscal years. Khoso Baluch has spoken on 6 earnings calls across 1 company, most recently for CorMedix Inc. on August 12, 2021. Processa Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Khoso Baluch spoke on are classified in the Healthcare sector. Other leadership on record at Processa Pharmaceuticals, Inc. includes George Ng (CEO and Board Member), Russell L. Skibsted (CFO), Russell Skibsted (CFO) and 7 others.

“On November 7, 2025, Mr. Khoso Baluch and Ms. Neha Motwani provided notices of each of their resignations from the Board of Directors (the "Board") of Longeveron Inc. (the "Company") to be effective immediately.”
Longeveron Inc. Form 8-K, filed November 12, 2025 · Read the filing

Khoso Baluch on recent calls

“We're gratified that despite the ongoing pandemic, we've not experienced significant disruption to CorMedix. As Phoebe described, there remains uncertainty over the FDA’s ability to conduct foreign inspections of a third-party CMO.”
CEO, CorMedix Inc. Q2 FY2021 Earnings Call ·
“On today’s earnings call, we will discuss the first quarter 2021 financial information and the overall progress CorMedix is making in bringing DEFENCATH to the U.S. market for its first indication for use as a catheter lock solution for hemodialysis patients through reduced catheter-related bloodstream infections.”
CEO, CorMedix Inc. Q1 FY2021 Earnings Call ·
“On today's earnings call, we will discuss fourth quarter and fiscal year 2020 financial information, and the overall progress CorMedix is making in bringing DEFENCATH to the US market for its first indication for use as a catheter lock solution for hemodialysis patients to reduce catheter-related bloodstream…”
CEO, CorMedix Inc. Q4 FY2020 Earnings Call ·
“On today’s earnings call, we will discuss several topics regarding the overall progress CorMedix is making in bringing DEFENCATH to the U.S. market for its first indication for use as a catheter lock solution for hemodialysis patients to prevent catheter-related bloodstream infections with subsequent expansion into…”
CEO, CorMedix Inc. Q3 FY2020 Earnings Call ·
“On today's earnings call, we will discuss several topics with you on the overall progress CorMedix is making in bringing DEFENCATH to the U.S. market for its first indication for use as a catheter lock solution for hemodialysis patients to prevent catheter-related bloodstream infections, with subsequent expansion into…”
CEO, CorMedix Inc. Q2 FY2020 Earnings Call ·

Affiliation history

Company network

Leadership on record at Processa Pharmaceuticals, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2021 CorMedix Inc. (CRMD) $366,700 $2,596,173
2020 CorMedix Inc. (CRMD) $425,000 $1,233,671
2019 CorMedix Inc. (CRMD) $387,885 $1,795,829

Recent activity